We recently contacted all stakeholders for the appraisal of cabozantinib for previously treated advanced hepatocellular carcinoma [ID3917] regarding a delay to this topic for operational reasons.
Cabozantinib for previously treated advanced hepatocellular carcinoma has now been rescheduled into the work programme and the appraisal is due to start late November 2021 and will be discussed at committee in early August 2022.
The new timelines are subject to the work programme capacity and we will continue to review our plans and update our stakeholders accordingly.